OncoC4 Announces NMPA Acceptance of Two IND Applications for Cesalatamig Combination Studies with ADCs and Pan-RAS Inhibitors

RegulatoryCesalatamigPositive

AI Analysis

Summary

OncoC4 announced that China's NMPA accepted two IND applications for studies combining cesalatamig with antibody-drug conjugates and pan-RAS inhibitors. Cesalatamig is also being evaluated in ongoing Phase 2 studies in the US and China.

Clinical Trial Data

Outcome Details

China's NMPA accepted two IND applications for cesalatamig combination studies with ADCs and pan-RAS inhibitors

Importance:4/10

Sentiment:

0.40

INDNMPAChinaimmuno-oncologycombination therapyADCpan-RAS inhibitorprivate company

Related Companies

$DFPH $UTHR $CPHI

Read the original article

Published by PR Newswire Pharma on October 19, 2026 11:16 AM

Read Original